3 edition of Symposium on the Clinical Significance of Quality of Life Measures in Cancer Patients (Mayo Clinic Proceedings Symposiums) found in the catalog.
Symposium on the Clinical Significance of Quality of Life Measures in Cancer Patients (Mayo Clinic Proceedings Symposiums)
by Mayo Foundation for Medical Education
Written in English
|The Physical Object|
Cancer and chemoradiotherapy have a significant adverse impact on the quality of life (QOL) of cancer patients. With the advent of new and more effective cancer therapies, patients with cancer are surviving longer than in the past. This has led to increased importance for maintaining good QOL in cancer by: 1. The PIQoL-AD has been used in several trials assessing quality of life (QoL) in parents of children with atopic dermatitis (AD), treated with pimecrolimus cream 1%. Secondary analysis of data from four trials (n = ) was undertaken to help interpret the meaningfulness (significance) of the QoL results. A combination of anchor-based and distribution-based Cited by:
Maximizing quality of life for cancer patients means that cancer treatment is focused on treating both the disease and the person. This form of treatment is also called palliative care. According to National Cancer Institute, the goal of palliative care is to prevent or treat, as early as possible, the symptoms and side effects of the disease. A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text.
In this pooled analysis, the authors examined correlations between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between clinically significant changes in QOL and patient-reported adverse events (AE). METHODS. Data from 6 lung cancer clinical trials that involved patients were by: Improving the Quality of Life for Lung Cancer Patients Draft2V5 – December 2, CC 2 Quality of Life and Patient Reported Outcomes: Relation to Major Clinical Outcomes Definitions of quality of life (QOL) and the individual components of which it consists for lung cancer patients may always be variable to an extent.
Looking at Spanish cities
Gore Creek watershed, Colorado
Ten year national health plan, 1967-1976.
Ali dagli occhi azzurri.
Planning at a time of no growth
Factors affecting non-response to cervical cytology screening in Norfolk
From the stone age to Christianity
The need of the city of New York for more water and where it can best be obtained
Duty on Steel-Wire Rods
People make the difference.
Put It Together (Tool Kit)
Office of the High Commissioner
Influence of alum and soap solutions of the permeability of concrete
Investigations into Scottish Borders Council and NHS Borders services for people with learning difficulties
The purpose of the Symposium in the Clinical Significance of Quality of Life Measures in Cancer Patients was to delineate in simple language the degree of consensus that existed regarding clinical significance. Symposium on Quality of Life in Cancer Patients Assessing Clinical Significance in Measuring Oncology Patient Quality of Life: Introduction to the Symposium, Content Overview, and Definition of Terms Author links open overlay panel Jeff A.
Sloan PhD a David Cella PhD c Marlene H. Frost PhD, RN b Gordon H. Guyatt MD d Mirjam A.G. Sprangers PhD Cited by: The entire Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients will be available for purchase as a bound booklet Cited by: symposium on quality of life in cancer patients Assessing the Clinical Significance of Single Items Relative to Summated Scores Author links open overlay panel Jeff A.
Sloan PhD a Neil Aaronson PhD b Joseph C. Cappelleri PhD, MPH c Diane L. Fairclough DRPH d Claudette Varricchio DSN, RN e THE CLINICAL SIGNIFICANCE CONSENSUS MEETING GROUPCited by: Patient, Clinician, and Population Perspectives on Determining the Clinical Significance of Quality-of-Life Scores.
Despite the success of screening and treatment of major cancers in the United States, cancer remains a chronic condition dominated by symptoms and treatment-related adverse by: The Clinical Significance Consensus Meeting Group of the Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients produced 6 articles regarding the clinical significance of quality of life (QOL) assessments in oncology.
The 6 articles deal with the methods used to date: group-vs-individual clinical significance Cited by: The Clinical Significance Consensus Meeting Group of the Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients produced 6 articles regarding the clinical significance of quality of life (QOL) assessments in by: ASCO GU Comparative Quality of Life in Patients Randomized Contemporaneously to Docetaxel or Abiraterone In the STAMPEDE Trial San Francisco, CA USA () In recent years, both docetaxel and abiraterone have been shown to improve overall survival when added to standard androgen deprivation therapy (ADT) for men with metastatic hormone.
Figure 1 - statistical significance and clinical irrelevance. The effect is the estimate of the impact for the treatment being tested. Many primary outcomes in cancer trials use time to event data looking at overall survival and progression-free survival. Time to event data is challenging because of incomplete data leading to censoring.
A QOL instrument was developed to measure the specific concerns of long term cancer survivors. The QOL-CS is based on previous versions of the QOL instrument developed by researchers at the City of Hope National Medical Centre (Grant, Padilla, and Ferrell). This instrument was revised over a one year pilot by Hassey-Dow and Ferrell.
The revised Cited by: The original six articles were presented at the Symposium on Clinical Significance of Quality of Life Measures in Cancer Patients at the Mayo. Objective: This report extracts important considerations for determining and applying clinically significant differences in quality of life (QOL) measures from six published articles written by 30 international experts in the field of QOL assessment and original six articles were presented at the Symposium on Clinical Significance of Quality of Life Measures in Cancer Patients Cited by: The entire Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients will be available for purchase as a bound booklet from the Proceedings Editorial Office at a later date.
A complete list of other Clinical Significance Consensus Meeting Group contributors to this article appears at the end of the by: The objective of this study is to describe the quality of life (QoL) in cancer patients with solid tumors and at different chemotherapy (CT) cycles.
A total of cancer patients were included. With some modification, the European Organization for Research and Treatment. Following the development of reliable and valid self-report questionnaires, health-related quality of life has been assessed in tens of thousands of patients and a wide variety of cancers.
This review is based on a selection of data published in the last decade and is intended primarily for healthcare by: Cancer can produce many different symptoms, some subtle and some not at all subtle.
An increasingly important issue in oncology is to evaluate quality of life (QoL) in cancer patients. The cancer-specific QoL is related to all stages of this by: The Clinical Significance Consensus Meeting Group of the Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients produced 6 articles regarding the clinical significance of quality of life (QOL) assessments in oncology.
Having a potentially life-threatening disease like cancer often leads people to examine their lives and look for meaning. In fact, this search for meaning may be the aspect of cancer that most often has a positive influence on life.
The fear of death that affects most people when they are diagnosed with cancer, often leads us to think about. Among the most widely used instruments to assess quality of life (QOL) in patients with cancer are the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30) and the Functional Assessment of Chronic Illness Therapy, cancer instrument (FACT-G).
This study compared these approaches in patients who had undergone esophagectomy for by: Introduction It is our pleasure to invite you to the 5th EORTC Quality of Life in Cancer Clinical Trials Conference which will be held in This event will give participants the opportunity to learn about the latest topics in quality of life (QOL) and patient reported outcomes research.
The two-day conference aims to. and in global quality of life (global QL) and the QLQ-C30 were completed by patients who received chemother- apy for either breast cancer or small-cell lung cancerFile Size: KB. The most recent studies supplemented their assessments with site-specific questionnaires.
Overall, 59 different instruments have been used to measure quality of life in cancer patients [Additional file 1]. The EORTC QLQ-C30 was found to be the most widely used cancer-specific instrument, and as the tables in this review show, the questionnaire Cited by: Introduction As patient assessment of health-related quality of life (HRQOL) in cancer clinical trials has increased over the years, so has the need to attach meaningful interpretations to differences in HRQOL scores between groups and changes within groups.
Determining what represents a minimally important difference (MID) in HRQOL scores is useful to clinicians, patients Cited by: